Sánchez ALF, Puente LL, Lares BEF, Milla VRH

Language: Spanish
References: 29
Page: 501-508
PDF size: 205.66 Kb.

ABSTRACT

Background: The endometrium is a very dynamic organ that experience several half-full processes by the ovarian secretion of estradiol and progesterone. The effect of hormones steroids, in the epithelial cells, endoteliales and estromales of the endometrium, is influenced by receptors of estrogens and progesterone.
Objective: determine if there are any differences in the density of the estrogen receptors (ER) between the normal endometrial, the simple and complex hyperplasia, the atypical hyperplasia and the.
Material and methods: A retrospective study comparative was made. We included 143 samples that were knit together in 5 categories of the following way: Normal endometrial (n = 38), Simple hyperplasia (n = 58), Complex hyperplasia (n = 22), Atypical hyperplasia (n = 9), Adenocarcinoma (n = 16). Immunohistochemistry method was used through estreptavidin biotin peroxidase diaminobenzidine. The samples were analyzed for computer image. Mendez modified technique for cell count was used. The statistical analysis included descriptive statistical. The differences between groups were analyzed using ANOVA-MANOVA and t of Student for independent samples (α = 0.05) and other statistical test.
Results: there were no statistical significant differences on the cell density with ER between the normal endometrial and the simple and complex hyperplasia. The estrogen receptors are decreased in the atypical hyperplasia and the endometrial adenocarcinoma.
Discussion: The gravity of the injury increases proportionally with the age; the most important factor in the reduction of the cells with estrogénicos receivers is the neoplastic transformation.

REFERENCES

1. Silverberg SG, Kurman RJ. Tumors of uterine corpus and gestational trophoblastic disease. In: Rosai J, Sobin LJ, Editors. Atlas of tumor pathology. 3th ed. Washington: AFIP, 1993;pp:18-47.

2. Gartner LP, Hiatt JL. Texto Atlas de Histología. 2a ed. Mexico: McGraw-Hill, 2003;pp:450-5.

3. Mylonas I, Jeschke U, Shabani N, Khun C, et al. Normal and malignant human endometrium express immunohistochemicaly estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 2005;25:1679-86.

4. Whitehead MI, Lane G, Dyer G, Towsend PT, et al. Oestradiol: the predominant intranuclear oestrogen in the endometrium of oestrogen treated postmenopausal women. Br J Obstet Gynecol 1981;88:914-8.

5. Taylor AH, Guzail M, Wahab M, Thompson JR, Al-Azzael E. Quantitative histonorphometric analysis of gonadal steroid receptor distribution in the normal human endometrium through the menstrual cycle. Histochem Cell Biol 2005;123:463-74.

6. Paul M, Cholewa K, Mazurek U, Witek A, Wilczok T. Estrogenreceptor beta delta 6 (ER beta delta 6) isoform in human endometrial hyperplasia and adenocarcinoma. Cancer Invest 2004;22: 211-18.

7. Witek A, Mazurek U, Paul M, Bierzinska-Macyszyn G, Wilczok T. Quantitative analysis of estrogen receptor-alpha and beta and exon 5 splicing variant m-RNA in endometrial hyperplasia in perimenopausal women. Folia Histochem Cytobiol 2002;39:119-21.

8. Gunin AG, Emelianov V, Tolmachev AS. Effect of adrenocorticotrophic hormona on the development of oestrogen-induced changes and hyperplasia formation in the mouse uterus. Reproduction 2002;123:601-11.

9. Enríquez-Domínguez B, Fuentes-González L, Jova-Rodríguez M, Robaina-Aguirre F. Estudio clínico-epidemiológico del adenocarcinoma de endometrio y sus precursores. Rev Cubana Obstet Ginecol 2003;29:1-7.

10. Kurman RJ, Kaminsky PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;15:403-12.

11. Kurman RJ, Norris HJ. Endometrium. In: Henson DE, Albores- Saavedra J, Editors. The pathology of incipient neoplasia. Philadelphia: Saunders, 1986;pp:265-77.

12. Mutter GL. Endometrial intraepitelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287-90.

13. Baak JP, Mutter GL, Robboy S, van Diest PJ, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103:2304-12.

14. Baak JP, Mutter GL. EIN and WHO 94. J Clin Pathol 2005;58:1-6.

15. Latta E, Chapman WB. PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 2002;14:59-65.

16. Huang SJ, Cheng L, Lewin KJ. Immunohistochemical estrogen receptor assessment in hyperplastic neoplastic and physiologic endometria. Pathol Res Pract 1991;187:487-95.

17. Kato H. Electron microscopical and immunohistochemical study of human endometrial carcinoma with special reference to localization of estrogen receptors and carcinoembryogenic antigen. Pathol Res Pract 1986;38:1553-62.

18. Papdimitriou CS, Athanasiadou S, Stylianidou A. Immunohistochemical detection of estrogen receptors on paraffin sections of normal, hyperplastic and carcinomatous endometrium. Oncology 1992;49:196-202.

19. Méndez I, Namihira D, Moreno L, Sosa C. El protocolo de investigación. Análisis morfométrico. México: Trillas, 1990.

20. Mylonas I, Jeschke U, Shabani N, Jun C, et al. Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium. Acta Histochem 2004;106:245-52.

21. Baak JP, Van Diermen B, Steinbakk A, Janssen E, et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum Pathol 2005;36:555-61.

22. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. Clin Endocrinol Metab 2000;85:2334-8.

23. Kurose K, Zhou XP, Araki T, Cannistra SA, et al. Frequent loss of PTEN expression is linked to elevated phosphorylated akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinoma. Am J Pathol 2002;158:1895-8.

24. Kimura F, Watanabe J, Hata H, Fujisawa T, et al. PTEN immunohistochemical expression is suppressed in G1 endometriod adenocarcinoma of the uterine corpus. J Can Res Clin Oncol 2004;130:161-8.

25. Bircan S, Ensari A, Ozturk S, Erdogan N, et al. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol Oncol Res 2005;11:32-39.

26. Vihko R, Jaen O, Kauppila A. Steroid receptors in normal,hiperplastic and malignant human endometria. Ann Clin Res 1980;12:208-15.

27. Uchikawa J, Shiozawa T, Shih HC, Miyamoto T, et al. Expression of steroid receptor coactivators and corepresoors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer 2003;98:2207-13.

28. Pilka R, Kudela M, Eriksson P, Cassien B. MMP-26 mRNA estrogen receptor alpha co-expression in normal and pathological endometrium. Ceska Gynekol 2005;70:56-62.

29. Teleman S, Mihailovici MS. Value of steroid receptors assessment in atypical endometrial hyperplasia. Rev Med Chir Soc Med Nat Iasi 2003;107:813-6.